Multi-centre Clinical Trial on Hormone Replacement Treatment in China

Multi-centre Clinical Trial on Hormone Replacement Treatment in China

This study is to evaluate the benefit/risk of hormone replacement treatment among early menopausal women in China. This is a multi-centre, random, prospective study.

Inclusion Criteria:

• going through amenorrhea above 6 months and within 5 years,
• aged 40 to 60 years,
• going though postmenopausal symptoms,
• serum E2 concentration <30pg/ml,
• serum FSH concentration >40IU/L.

Exclusion Criteria:

• uterine fibroid diameter≥5cm,
• history of diabetes or hypertension,
• history of thromboembolism, severe endometriosis, epilepsy, asthma, hyperprolactinemia,
• first degree relative had a history of breast cancer,
• being in severe or unstable condition of somatic diseases,
• receiving HRT in the past 3 month,
• drug or alcohol abuse in the past 3 month,
• endometrial thickness ≥0.5cm after withdrawal bleeding,
• being allergic to the medicine,
• participating in other clinical trials within 1 month ago.